A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s...
MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology...
Engineered Camelina is intended to enable the land-based production of omega-3 oils used in aquafeed, petfood and human nutritionWOBURN, Mass....
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied dosesWALTHAM,...
Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months...
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of...
-- The United States FDA Clears Initiation of Efficacy Trial in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Patients A Phase...
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy...
Orders for Sharps Securegard 1mL and 3mL syringes are on the water, introducing a line of competitively priced, low waste,...
– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis – – American Heart Association to work with...
The Site Initiation Visit for the BWH clinical staff is complete and a shipment of LIBERTY investigational units was deliveredBRAINTREE,...
– Company also receives short extension of its credit agreement until July 31, 2024 –MINNEAPOLIS, June 17, 2024 (GLOBE NEWSWIRE)...
WEST PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- Rennova Health, Inc. (OTC: RNVA) is pleased to announce that...
~ Emphasizes Strong Cash Position, No Debt, and A Dedicated Management Team Focused on Delivering Growth and Value to Shareholders...
COLD SPRING HARBOR, N.Y., June 17, 2024 /PRNewswire/ -- Things aren't always as they seem. Take pancreatic cancer, for example. In...
AMSTERDAM, June 17, 2024 /PRNewswire/ -- Monday, at HLTH Europe, the Trustworthy & Responsible AI Network (TRAIN), a consortium of healthcare...
DUBAI, UAE, June 17, 2024 /PRNewswire/ -- XRP Healthcare proudly announces the release of Issue 3 of the highly anticipated...
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71%...
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses...